Crossmark

The efficacy and safety of induction chemotherapy combined with sintilimab followed by concurrent chemoradiotherapy plus sintilimab sequencing maintaining with sintilimab for patients with unresectable locally advanced esophageal squamous cell carcinoma

Crossref DOI link: https://doi.org/10.1186/s12885-025-13457-w

Published Online: 2025-01-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Ruifeng https://orcid.org/0009-0006-2508-7781
Guo, Tianhui

Wang, Qi

Gao, Wen

Yu, Yimiao

Zhang, Jun

Fu, Wenqian

Wang, Haiji

Zhang, Biyuan
Funding

Funding for this research was provided by:

Natural Science Foundation of Shandong Province (ZR2023QH519)

Wu Jieping Medical Foundation (No.320.6750.2023-17-30)
License Information

Text and Data Mining valid from 2025-01-16

Version of Record valid from 2025-01-16
More Information

Article History

Received: 11 September 2024

Accepted: 6 January 2025

First Online: 16 January 2025

Declarations

:

: This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of the Affiliated Hospital of Qingdao University (Approval No. QYFY WZLL 28684). All participants provided informed consent prior to their inclusion in the study. In cases where participants were unable to provide consent, their legal representatives provided consent on their behalf.

: The authors affirm that human research participants provided informed consent for publication of the images in Figs. , , , and ; Tables 1, 2 and 3.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below